相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting Phosphatidylserine with Calcium-Dependent Protein-Drug Conjugates for the Treatment of Cancer
Ran Li et al.
MOLECULAR CANCER THERAPEUTICS (2018)
iCFN: an efficient exact algorithm for multistate protein design
Mostafa Karimi et al.
BIOINFORMATICS (2018)
Antibody-Drug Conjugates for Cancer Treatment
John M. Lambert et al.
ANNUAL REVIEW OF MEDICINE, VOL 69 (2018)
Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
Guangmin Li et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Loss of expression of the recycling receptor, FcRn, promotes tumor cell growth by increasing albumin consumption
Rafal Swiercz et al.
ONCOTARGET (2017)
ABiparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
John Y. Li et al.
CANCER CELL (2016)
New developments for antibody-drug conjugate-based therapeutic approaches
Bart E. C. G. de Goeij et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Downregulation of the neonatal Fc receptor expression in non-small cell lung cancer tissue is associated with a poor prognosis
Emilie Dalloneau et al.
ONCOTARGET (2016)
Antibody Drug Conjugates: Nonclinical Safety Considerations
Mary Jane Masson Hinrichs et al.
AAPS JOURNAL (2015)
FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin
Michal Pyzik et al.
JOURNAL OF IMMUNOLOGY (2015)
Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
Robert P. Lyon et al.
NATURE BIOTECHNOLOGY (2015)
The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells
Sripad Ram et al.
MABS (2014)
Antibody-Drug Conjugates in Cancer Therapy
Eric L. Sievers et al.
ANNUAL REVIEW OF MEDICINE, VOL 64 (2013)
The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics
Siva Charan Devanaboyina et al.
MABS (2013)
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy et al.
NATURE GENETICS (2013)
Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9
Javier Chaparro-Riggers et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2011)
PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions
Mats H. M. Olsson et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2011)
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy
Howard A. Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Software Framework for the Analysis of Complex Microscopy Image Data
Jerry Chao et al.
IEEE TRANSACTIONS ON INFORMATION TECHNOLOGY IN BIOMEDICINE (2010)
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
Tomoyuki Igawa et al.
NATURE BIOTECHNOLOGY (2010)
Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels
C Vaccaro et al.
NATURE BIOTECHNOLOGY (2005)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin et al.
CANCER CELL (2004)
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin
CD Austin et al.
MOLECULAR BIOLOGY OF THE CELL (2004)
Compensation for loss of ligand activity in surface plasmon resonance experiments
RJ Ober et al.
ANALYTICAL BIOCHEMISTRY (2002)
分享论文
